
Alector Inc (ALEC) Stock Forecast & Price Target
Alector Inc (ALEC) Analyst Ratings
Bulls say
Alector Inc exhibits a promising outlook due to its innovative therapeutic approach targeting neurodegeneration, particularly through its differentiated transferrin receptor (TfR) binding technology, which has shown significantly enhanced brain uptake in non-human primates (NHPs). The company’s pipeline, which includes late-stage programs like AL137, AL050, and ADP064-ABC, represents substantial potential given the larger indications they target, suggesting that positive clinical data could yield considerable upside for investors. Furthermore, the company’s commitment to utilizing standardized Alzheimer’s disease biomarkers enhances the likelihood of demonstrating clinically meaningful results, bolstering confidence in the overall efficacy of Alector’s therapies.
Bears say
Alector Inc's recent downgrade to Neutral is largely attributed to the failure of the INFRONT-3 trial for latozinemab, which did not meet its primary endpoint and raises significant translational biology risks. Additional concerns stem from potential failures in their pipeline products, AL001 and AL002, regarding both regulatory approval and their ability to achieve projected peak commercial revenues, compounded by risks of negative trial results or unexpected toxicities. The company’s reliance on biomarker modulation without a demonstrated clinical impact in current trials further underscores the uncertainties surrounding its therapeutic approaches, which contributes to a negative financial outlook.
This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.
Alector Inc (ALEC) Analyst Forecast & Price Prediction
Start investing in Alector Inc (ALEC)
Order type
Buy in
Order amount
Est. shares
0 shares